GFibers

One in three suffers from a brain disease or cancer and currently there are no “cures” as drugs do not reach the brain at viable doses. The clinical translation success rate of new drugs for brain diseases remains the lowest of all therapeutic areas and current animal models are unreliable to inform translation. Our proprietary patented GFiberS platform technology enables the on-target non-invasive nose-to-brain delivery of peptide therapies for brain diseases and tumours. GFiberS are manufactured under continuous and industrial amenable processes and our team is pioneering proprietary human organ-on-chip nose-to-brain models for speeding up the translation of brain therapies.